As you mentioned, it is a proposed decision. The alternatives working group is looking at alternatives to imidacloprid, and at whether those alternatives have what we call MRLs, maximum residue limits, so whether there would be any market access challenges.
If there is a decision moving forward to do the phase-out, what we would like to ensure is that growers have access to alternatives that are widely accepted by trading partners because that is required as part of Canada's trading requirements.